Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Transcatheter Mitral Valve Replacement for Severe Mitral Regurgitation: A Global Study

Transcatheter Mitral Valve Replacement for Severe Mitral RegurgitationSymptomatic mitral regurgitation is associated with high morbidity and mortality that can be alleviated partly by surgical mitral valve replacement. However, many patients do not undergo surgery. Transcatheter mitral valve replacement is an appealing option for this selected patient group.

 

This study aimed to examine the effectiveness and safety of transcatheter mitral valve replacement in a cohort of patients with native valve mitral regurgitation and high surgical risk.

 

Patients undergoing transapical transcatheter mitral valve replacement with a self-expanding prosthesis were prospectively enrolled and their short-term (30-day) outcomes were assessed.

 

Thirty high-surgical-risk patients (STS predicted risk of mortality score of 7.6 ± 5.7%) with grade 3 or 4 mitral regurgitation received the device, and there was successful implantation in 28 of them (93.3%).

 

There were no deaths, strokes, or peri-procedural infarctions. One patient died at 13 days from a hospital-acquired infection. One patient presented leaflet thrombosis that was resolved by increasing the range of anticoagulation with warfarin.

 

At 30 days, an echocardiography showed mild regurgitation in 1 patient, and absolutely none in the remaining 26 patients. There was also a significant reduction in the left ventricular end-diastolic and end-systolic volume indexes.

 

Seventy-five percent of the patients reported mild or no symptoms at follow-up.

 

Successful device implantation free of mortality, stroke, and prosthesis malfunction was 86.6%.

 

Conclusion

Transcatheter mitral valve replacement is an effective and safe therapy for selected patients with severe mitral regurgitation and high surgical risk.

 

Original title: Transcatheter Mitral Valve Replacement for Patients with Symptomatic Mitral Regurgitation. A Global Feasibility Trial.

Reference: David W.M. Muller et al. J Am Coll Cardiol. 2016 Dec 20. [Epub ahead of print].


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...